Onyx Appoints Edward Kenney Executive Vice President and Chief Business Officer

Onyx Appoints Edward Kenney Executive Vice President and Chief
Business Officer 


RICHMOND, Calif., June 3  /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
(NASDAQ:ONXX) today announced the appointment of Edward Kenney as executive
vice president and chief business officer.   Mr. Kenney joins the company from
Cell Therapeutics, Inc. where he held the position of executive vice president
and chief operating officer.  In this newly created position, Mr. Kenney will
be responsible for all commercial activities including sales and marketing and
business development.

"Ed's experience building a commercial infrastructure and bringing products
successfully to market is a critical asset as we continue to advance our lead
drug candidate, BAY 43-9006, through the later stages of clinical development,"
said Hollings Renton, Onyx's chairman and chief executive officer.  "His
expertise ranges from sales, marketing and business development to medical
affairs and manufacturing.  We are delighted to welcome him to the Onyx team at
this important stage in our corporate development."

Mr. Kenney worked for five years at Cell Therapeutics, where he managed the
introduction of the company's first product in the U.S. and Europe.  Prior to
joining Cell Therapeutics, Mr. Kenney served as vice president, marketing and
sales, at CellPro, Inc.  From 1987 to 1996, he held various management
positions with Chiron Corporation, most recently as vice president of marketing
and sales for Chiron Therapeutics.  While at Chiron, he was responsible for the
U.S. launch of Proleukin for kidney cancer and for increasing revenues of
Aredia to treat bone pain in cancer patients.  Before that, he was with
Boehringer Ingelheim Pharmaceuticals and the Bristol-Myers Company.  Mr. Kenney
earned his M.S. and B.S. degrees from Ohio State University.

Onyx Pharmaceuticals is engaged in the development of novel cancer therapies
that target the molecular basis of cancer.  With its collaborators, the company
is developing small molecule drugs, including BAY 43-9006 with Bayer
Pharmaceuticals Corporation.  For more information about Onyx's pipeline and
activities, visit the company's website at http://www.onyx-pharm.com/.

This press release contains forward-looking statements regarding expectations
about the development of BAY 43-9006.  These forward-looking statements involve
a number of risks and uncertainties that could cause actual events to differ
from the company's expectations.  These risks are addressed in the company's
periodic reports filed with the Securities and Exchange Commission, including
but not limited to its Annual Report on Form 10-K filed on March 15, 2004 and
its Quarterly Reports on Form 10-Q. 

DATASOURCE: Onyx Pharmaceuticals, Inc.



CONTACT:  Julie Wood of Onyx Pharmaceuticals, Inc., [phone]



Web site:  http://www.onyx-pharm.com/ 

Copyright